



## Tony Gordon

After obtaining a PhD in Carcinogenesis research at the University of Nottingham in 1995, Dr Gordon worked for 7 years at the Institute of Cancer Research (London, UK) in Molecular Cytogenetics investigating pediatric sarcomas. In early 2006 Dr Gordon joined a software start-up, BlueGnome, to start their CytoChip microarray product line. In 2008 Dr Gordon started the 24sure pre-implantation genetic screening (PGS) microarray product line within BlueGnome. Currently 24sure been used to analyse the copy number content of over 300,000 embryo biopsies and has been shown by randomized control clinical trials to improve IVF outcomes. In 2012 BlueGnome was sold to Illumina for \$88M. In 2013 Dr Gordon joined Genesis Genetics, the leading global company for PGD and PGS. Dr Gordon is the Managing Director for Genesis Genetics USA, plus Laboratory Director for Genesis Genetics UK laboratories. Dr Gordon is also a UK State Registered Clinical scientist, with nearly 20 years' experience of clinical diagnostics.

